SFM
BEAM icon

Sphera Funds Management’s Beam Therapeutics BEAM Stock Holding History

Sphera Funds Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,425
Closed -$3.66M – 122
2021
Q2 		$3.66M Buy
+28,425
New +$2.26M 0.25% 83
2020
Q2 		– Sell
-264,681
Closed -$4.76M – 93
2020
Q1 		$4.76M Buy
+264,681
New +$5.75M 0.6% 37

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's BEAM Position: Q3 2021 in Review

Sphera Funds Management sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 28,425 shares — an estimated $3.66M sold.

Sphera Funds Management first reported a position in BEAM in Q1 2020 and held it in 2 quarters. The position peaked at $4.76M in Q1 2020. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Sphera Funds Management reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Sphera Funds Management sold 28,425 Beam Therapeutics shares in Q3 2021, an estimated $3.66M.
  • Sphera Funds Management first reported a position in Beam Therapeutics in Q1 2020 and held it in 2 quarters.
  • Sphera Funds Management's Beam Therapeutics position peaked at $4.76M in Q1 2020.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.